Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, St Leonards, NSW, Australia.
Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, St Leonards, NSW, Australia.
Public Health. 2022 Oct;211:97-104. doi: 10.1016/j.puhe.2022.06.022. Epub 2022 Sep 2.
The cost of treating metastatic colorectal cancer places a significant economic burden on individuals, populations, and health care. However, there is a paucity of information on the costs of the contemporary management of metastatic colorectal cancer. This systematic review aims to review the literature to estimate the direct cost of treating metastatic colorectal cancer.
Systematic review.
MEDLINE, Embase, Web of Science, Evidence-Based Medicine Reviews: National Health Service Economic Evaluation Database Guide, EconLit, and grey literature from the 1st of January 2000 to the 1st of February 2020 were all searched for studies reporting the direct costs of treating metastatic colorectal cancer. The methodological quality of the included studies was assessed using the Evers' Consensus on Health Economic Criteria checklist.
In total, 39,489 records were retrieved, and 29 studies were included. Costs of treating metastatic colorectal cancer varied because of the heterogeneity of treatment. Studies reported average costs ranged from $12,346 to $293,461. Studies that included the cost of systemic therapy reported an estimated cost of almost $300,000.
The existing evidence indicates that the cost of treating metastatic colorectal cancer places a significant economic burden on healthcare systems despite differences in methodology and treatment heterogeneity. Future research needs to define the cost components of treating metastatic colorectal cancer to improve comparability and examine the relationship between spending, overall survival, and quality of life. Identifying these costs and their impact on health care budgets can help policymakers plan health system expenditure.
转移性结直肠癌的治疗费用给个人、人群和医疗保健带来了巨大的经济负担。然而，关于转移性结直肠癌当代管理成本的信息却很少。本系统评价旨在回顾文献，以评估转移性结直肠癌治疗的直接成本。
系统评价。
从 2000 年 1 月 1 日至 2020 年 2 月 1 日，检索 MEDLINE、Embase、Web of Science、循证医学评论：国家卫生服务经济评估数据库指南、EconLit 和灰色文献，以查找报告转移性结直肠癌治疗直接成本的研究。使用 Evers 共识健康经济标准检查表评估纳入研究的方法学质量。
共检索到 39489 条记录，纳入了 29 项研究。由于治疗的异质性，转移性结直肠癌的治疗成本有所不同。报告的成本研究的平均成本从 12346 美元到 293461 美元不等。包括系统治疗成本的研究报告了近 30 万美元的估计成本。
现有证据表明，尽管在方法学和治疗异质性方面存在差异，但治疗转移性结直肠癌的成本仍给医疗保健系统带来了巨大的经济负担。未来的研究需要确定治疗转移性结直肠癌的成本构成，以提高可比性，并研究支出、总生存率和生活质量之间的关系。确定这些成本及其对医疗保健预算的影响可以帮助决策者规划医疗保健系统支出。
